Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Eribulin and Lenvatinib in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
- Status
- COMPLETED
- Phase
- NA
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
- Status
- COMPLETED
- Phase
- PHASE1
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
- Status
- COMPLETED
- Phase
- N/A
A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
- Status
- COMPLETED
- Phase
- PHASE1
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
- Status
- COMPLETED
- Phase
- PHASE2
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE3
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
- Status
- COMPLETED
- Phase
- PHASE2
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
- Status
- COMPLETED
- Phase
- PHASE1
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
- Status
- COMPLETED
- Phase
- PHASE3